Technical Analysis for ENDP - Endo Health Solutions Inc.

Grade Last Price % Change Price Change
grade C 6.04 -2.27% -0.14
ENDP closed down 2.27 percent on Friday, January 17, 2020, on approximately normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical ENDP trend table...

Date Alert Name Type % Chg
New Uptrend Bullish 0.00%
Upper Bollinger Band Walk Strength 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup -2.27%
Upper Bollinger Band Walk Strength -2.27%
Wide Bands Range Expansion -2.27%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Endo Health Solutions Inc. provides specialty healthcare solutions in the United States and internationally. The company's Endo Pharmaceuticals segment offers branded prescription products, including Lidoderm, Opana ER, Percocet, Voltaren Gel, Frova, Supprelin LA, Vantas, Valstar, and Fortesta Gel for pain, urology, endocrinology, and oncology. Its Qualitest segment provides non-branded generic products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health, and hypertension markets. The company's AMS segment offers various technology solutions comprising AMS 700 MS series, AMS 800 artificial urinary sphincter, GreenLight XPS laser system, Elevate transvaginal pelvic floor repair system, and Monarc subfascial hammock products in the areas of men's and women's health, and BPH therapy. Its HealthTronics segment provides urological services, such as lithotripsy, prostate treatment, anatomical pathology, and electronic medical record services to urologists, hospitals, surgery centers, and clinics; and manufactures, sells, and maintains medical devices for tissue and tumor ablation. The company's products under development primarily include Aveed, an injectable testosterone preparation to treat male hypogonadism; BEMA Buprenorphine, a transmucosal form of buprenorphine in Phase III trials for treating moderate to severe chronic pain; ODM-201, an androgen receptor antagonist in Phase II clinical testing to treat castrate resistant prostate cancer; and EN3342, a polyurethane implant in Phase I/II trials for the maintenance treatment of schizophrenia in adults. It serves pharmacy chains directly; and hospitals, governmental agencies, pharmacies, and physicians through wholesale drug distributors. The company was formerly known as Endo Pharmaceuticals Holdings Inc. and changed its name to Endo Health Solutions Inc. in May 2012. Endo Health Solutions Inc. was founded in 1997 and is headquartered in Malvern, Pennsylvania.
Pain Surgery Chemical Compounds Organic Compounds Technology Solutions Tumor Pain Management Schizophrenia Central Nervous System Disorders Healthcare Solutions Opioids Prescription Products Severe Chronic Pain Buprenorphine Laser System Lithotripsy Diclofenac

Is ENDP a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.49
52 Week Low 1.97
Average Volume 6,664,517
200-Day Moving Average 4.63
50-Day Moving Average 4.73
20-Day Moving Average 4.90
10-Day Moving Average 5.08
Average True Range 0.39
ADX 26.84
+DI 39.41
-DI 9.80
Chandelier Exit (Long, 3 ATRs ) 5.17
Chandelier Exit (Short, 3 ATRs ) 5.44
Upper Bollinger Band 5.99
Lower Bollinger Band 3.80
Percent B (%b) 1.02
BandWidth 44.56
MACD Line 0.28
MACD Signal Line 0.11
MACD Histogram 0.1762
Fundamentals Value
Market Cap 1.35 Billion
Num Shares 223 Million
EPS -23.00
Price-to-Earnings (P/E) Ratio -0.26
Price-to-Sales 0.37
Price-to-Book 1.85
PEG Ratio -0.11
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.63
Resistance 3 (R3) 6.65 6.48 6.53
Resistance 2 (R2) 6.48 6.33 6.47 6.49
Resistance 1 (R1) 6.26 6.24 6.18 6.24 6.46
Pivot Point 6.09 6.09 6.05 6.08 6.09
Support 1 (S1) 5.87 5.94 5.79 5.85 5.62
Support 2 (S2) 5.70 5.85 5.69 5.59
Support 3 (S3) 5.48 5.70 5.55
Support 4 (S4) 5.46